Indo Us Biotech share news, announcements and annual reports
NSE: INDOUSBSE: 541304Agricultural Food & other ProductsSmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹72.37.
28 Oct: open ₹83.00, high ₹86.84, low ₹80.35
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹174 Cr2,332nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.20
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,05,46733.5% delivered
Indo Us Biotech has 104 announcements on record, routine notices left out; 4 in the 30 days to 29 Oct 2026, the latest on 24 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Indo Us Biotech quarterly results
The board meets on 30 Oct 2026 to consider financial results
Notice filed 24 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Indo Us Biotech annual reports, presentations and earnings calls
The company's own documents, latest first.Indo Us Biotech financials, year by year
Annual reports2
- Annual report, year to Mar 20265 Sep 2026
- Annual report, year to Mar 202528 Aug 2025
Indo Us Biotech share news and announcements
Newest first. Page 1 of 3.
Oct 2026
24 Oct · Board meeting
Sep 2026
30 Sep · Meeting
5 Sep · Board meeting
Aug 2026
12 Aug · Results
5 Aug · Meeting
4 Aug · Board meeting
Jul 2026
4 Jul · Meeting
3 Jul · Board meeting
Jun 2026
17 Jun · Management
16 Jun · Management
May 2026
29 May · Results
21 May · Board meeting
Apr 2026
22 Apr · Management
22 Apr · Management
21 Apr · Disclosure of material issue
21 Apr · Management
Mar 2026
11 Mar · Legal
The exchange asked on 10 Mar 2026
Feb 2026
Jan 2026
21 Jan · Results
21 Jan · Board meeting
12 Jan · Board meeting
8 Jan · Legal
Exchange has sought clarification from Indo Us Biotech Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Dec 2025
Nov 2025
15 Nov · Results
15 Nov · Board meeting
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 12 Aug 2026Resultsdown 0.05%0.0 pts vs Nifty 500market median −0.7% · five sessions +8.0% (+8.9 pts vs Nifty 500) · volume 0.2× usual · delivery −1.1 pts against usual · The announcement
- 1 Jun 2026Resultsdown 0.04%+0.9 pts vs Nifty 500market median −0.7% · five sessions −2.1% (−1.3 pts vs Nifty 500) · volume 1.1× usual · delivery +12.6 pts against usual · The announcement
- 23 Apr 2026Board or managers changeddown 1.57%−0.8 pts vs Nifty 500market median 0.0% · five sessions −2.6% (−2.0 pts vs Nifty 500) · volume 0.3× usual · delivery +10.0 pts against usual · The announcement
- 22 Apr 2026Board or managers changeddown 0.03%+0.2 pts vs Nifty 500market median 0.0% · five sessions −4.7% (−3.5 pts vs Nifty 500) · volume 0.6× usual · delivery +2.1 pts against usual · The announcement
- 21 Jan 2026Resultsup 2.47%+3.0 pts vs Nifty 500market median −0.7% · five sessions +21.5% (+20.9 pts vs Nifty 500) · volume 2.5× usual · delivery −23.3 pts against usual · The announcement
- 13 Aug 2025Resultsdown 0.85%−1.4 pts vs Nifty 500market median −0.7% · five sessions −10.0% (−12.6 pts vs Nifty 500) · volume 0.7× usual · delivery −27.5 pts against usual · The announcement
- 21 Nov 2024Dividenddown 1.99%−1.2 pts vs Nifty 500market median 0.0% · five sessions +2.5% (−0.6 pts vs Nifty 500) · volume 0.4× usual · delivery −6.0 pts against usual · The announcement
- 14 Nov 2024Resultsup 9.79%+9.6 pts vs Nifty 500market median −0.7% · five sessions +8.8% (+7.4 pts vs Nifty 500) · volume 1.8× usual · delivery −26.2 pts against usual · The announcement
Indo Us Biotech results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Cash generated before tax | Year to date to Sep 2023 | Standalone | −0.14 | −1.21 | −780.6% | 18 Dec 2023 | 11 Jul 2024 |
| Face value of a share | Year to date to Sep 2023 | Standalone | 10.00 | 3,848.62 | +38,386.2% | 18 Dec 2023 | 11 Jul 2024 |
| Change in other current assets | Year to date to Sep 2023 | Standalone | −0.02 | 0.02 | +200.0% | 18 Dec 2023 | 11 Jul 2024 |
| Cash from operations | Year to date to Sep 2023 | Standalone | −0.08 | −1.15 | −1,413.5% | 18 Dec 2023 | 11 Jul 2024 |
| Loans given | Year to date to Sep 2023 | Standalone | 0.72 | −0.72 | −200.0% | 18 Dec 2023 | 11 Jul 2024 |
| Current tax | Year to date to Sep 2023 | Standalone | 0.46 | 0.21 | −54.7% | 18 Dec 2023 | 11 Jul 2024 |
| Cash from investing | Year to date to Sep 2023 | Standalone | 1.35 | −1.35 | −200.0% | 18 Dec 2023 | 11 Jul 2024 |
| Borrowings raised | Year to date to Sep 2023 | Standalone | 0.07 | 1.64 | +2,214.6% | 18 Dec 2023 | 11 Jul 2024 |
| Change in other current liabilities | Year to date to Sep 2023 | Standalone | −0.71 | 0.71 | +200.0% | 18 Dec 2023 | 11 Jul 2024 |
| Deferred tax | Year to date to Sep 2023 | Standalone | −0.09 | 0.17 | +298.6% | 18 Dec 2023 | 11 Jul 2024 |